Cyclooxygenase-2 is a target gene of Rho GDP dissociation inhibitor β in breast cancer cells

Cancer Research

Volumn 67, Issue 22, 2007, Pages 10694-10702

  Schunke, Dario ^a   Span, Paul ^b   Ronneburg, Henrike ^a   Dittmer, Angela ^a   Vetter, Martina ^a   Holzhausen, Hans Jürgen ^a   Kantelhardt, Eva ^a   Krenkel, Sylke ^c   Müller, Volkmar ^c   Sweep, Fred C G J ^b   Thomssen, Christoph ^a   Dittmer, Jürgen ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; RHO FACTOR; RNA; TRANSCRIPTION FACTOR NFAT;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING;

BIOPSY; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CYCLOOXYGENASE 2; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROTO-ONCOGENE PROTEIN C-ETS-1; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 36348938027     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1621     Document Type: Article

References (47)

1. Olofsson B. Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal 1999;11:545-54.
2. Dovas A, Couchman JR. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem J 2005;390:1-9.
3. DerMardirossian C, Bokoch GM. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol 2005;15:356-63.
4. Fukata M, Kaibuchi K. Rho-family GTPases in cadherin-mediated cell-cell adhesion. Nat Rev Mol Cell Biol 2001;2:887-97.
5. Titus B, Schwartz MA, Theodorescu D. Rho proteins in cell migration and metastasis. Crit Rev Eukaryot Gene Expr 2005;15:103-14.
6. Bhowmick NA, Ghiassi M, Bakin A, et al. Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 2001;12:27-36.
7. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 2002;87:635-44.
8. Scherle P, Behrens T, Staudt LM. Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes. Proc Natl Acad Sci U S A 1993;90:7568-72.
9. Gildea JJ, Seraj MJ, Oxford G, et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 2002;62:6418-23.
10. Titus B, Frierson HF, Jr., Conaway M, et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 2005;65:7320-7.
11. Tapper J, Kettunen E, El-Rifai W, Seppala M, Andersson LC, Knuutila S. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet 2001;128:1-6.
12. Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF, Jr. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 2004;10:3800-6.
13. Ota T, Maeda M, Suto S, Tatsuka M. LyGDI functions in cancer metastasis by anchoring Rho proteins to the cell membrane. Mol Carcinog 2004;39:206-20.
14. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-9.
15. Vetter M, Blumenthal SG, Lindemann RK, et al. Ets1 is an effector of protein kinase Cα in cancer cells. Oncogene 2005;24:650-61.
16. Dittmer J. The biology of the Ets1 proto-oncogene. Mol Cancer 2003;2:29.
17. Foos G, Hauser C. The role of Ets transcription factors in mediating cellular transformation. In: Gossen M, Kaufmann J, Triezenberg SJ, editors. Handbook of experimental pharmacology, vol. 166. Heidelberg: Springer;2004. p. 259-75.
18. Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005;41:2462-78.
19. Sioud M, Sorensen DR. A nuclease-resistant protein kinase Ca ribozyme blocks glioma cell growth. Nat Biotechnol 1998;16:556-61.
20. Ways DK, Kukoly CA, deVente J, et al. MCF-7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 1995;95:1906-15.
21. DerMardirossian C, Rocklin G, Seo JY, Bokoch GM. Phosphorylation of RhoGDI by Src regulates Rho GTPase binding and cytosol-membrane cycling. Mol Biol Cell 2006;17:4760-8.
22. Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007;67:1580-8.
23. Dittmer A, Vetter M, Schunke D, et al. Parathyroid hormone-related protein regulates tumor-relevant genes in breast cancer cells. J Biol Chem 2006;281:14563-72.
24. Lindemann RK, Ballschmieter P, Nordheim A, Dittmer J. Transforming growth factor β regulates parathyroid hormone-related protein expression in MDA-MB-231 breast cancer cells through a novel Smad/Ets synergism. J Biol Chem 2001;276:46661-70.
25. Dittmer A, Dittmer J. β-Actin is not a reliable loading control in Western blot analysis. Electrophoresis 2006;27:2844-5.
26. Krynetski EY, Krynetskaia NF, Gallo AE, Murti KG, Evans WE. A novel protein complex distinct from mismatch repair binds thioguanylated DNA. Mol Pharmacol 2001;59:367-74.
27. Iniguez MA, Martinez-Martinez S, Punzon C, Redondo JM, Fresno M. An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J Biol Chem 2000;275:23627-35.
28. Nakazawa Y, Suzuki M, Manabe N, et al. Cooperative interaction between ETS1 and GFI1 transcription factors in the repression of Bax gene expression. Oncogene 2007;26:3541-50.
29. Nakerakanti SS, Kapanadze B, Yamasaki M, Markiewicz M, Trojanowska M. Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem 2006;281:25259-69.
30. Yiu GK, Toker A. NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2. J Biol Chem 2006;281:12210-7.
31. Okamura H, Aramburu J, Garcia-Rodriguez C, et al. Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Mol Cell 2000;6:539-50.
32. Jauliac S, Lopez-Rodriguez C, Shaw LM, Brown LF, Rao A, Toker A. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol 2002;4:540-4.
33. Groysman M, Hornstein I, Alcover A, Katzav S. Vav1 and Ly-GDI two regulators of Rho GTPases, function cooperatively as signal transducers in T cell antigen receptor-induced pathways. J Biol Chem 2002;277:50121-30.
34. Delannoy-Courdent A, Mattot V, Fafeur V, et al. The expression of an Ets1 transcription factor lacking its activation domain decreases uPA proteolytic activity and cell motility, and impairs normal tubulogenesis and cancerous scattering in mammary epithelial cells. J Cell Sci 1998;111:1521-34.
35. Kita D, Takino T, Nakada M, Takahashi T, Yamashita J, Sato H. Expression of dominant-negative form of Ets-1 suppresses fibronectin-stimulated cell adhesion and migration through down-regulation of integrin α5 expression in U251 glioma cell line. Cancer Res 2001;61:7985-91.
36. Hever A, Oshima RG, Hauser CA. Ets2 is not required for Ras or Neu/ErbB-2 mediated cellular transformation in vitro. Exp Cell Res 2003;290:132-43.
37. Zhang Y, Zhang B. D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness. Cancer Res 2006;66:5592-8.
38. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5.
39. Hiraga T, Myoui A, Choi ME, Yoshikawa H, Yoneda T. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-β enhances bone metastases in breast cancer. Cancer Res 2006;66:2067-73.
40. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
41. Larkins TL, Nowell M, Singh S, Sanford GL. Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 2006;6:181.
42. Houlard M, Arudchandran R, Regnier-Ricard F, et al. Vav1 is a component of transcriptionally active complexes. J Exp Med 2002;195:1115-27.
43. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, et al. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 2005;7:39-49.
44. Katzav S. Vav1: an oncogene that regulates specific transcriptional activation of T cells. Blood 2004;103:2443-51.
45. Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 2005;20:539-50.
46. Chen J, Zhao M, Rao R, Inoue H, Hao CM. C/EBPβ and its binding element are required for NFκB-induced COX2 expression following hypertonic stress. J Biol Chem 2005;280:16354-9.
47. Ballschmieter P, Braig M, Lindemann RK, Nordheim A, Dittmer J. Splicing variant ΔVII-Ets1 is downregulated in invasive Ets1-expressing breast cancer cells. Int J Oncol 2003;22:849-53.